References of "European Heart Journal"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailSecondary tricuspid regurgitation in patients with left ventricular systolic dysfunction: cause for concern or innocent bystander?
Lancellotti, Patrizio ULiege; Fattouch, Khalil; Go, Yun Yun

in European Heart Journal (2018), 39(39), 3593-3595

Detailed reference viewed: 36 (1 ULiège)
Full Text
Peer Reviewed
See detailThe performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability.
Knuuti, Juhani; Ballo, Haitham; Juarez-Orozco, Luis Eduardo et al

in European Heart Journal (2018)

Aims: To determine the ranges of pre-test probability (PTP) of coronary artery disease (CAD) in which stress electrocardiogram (ECG), stress echocardiography, coronary computed tomography angiography ... [more ▼]

Aims: To determine the ranges of pre-test probability (PTP) of coronary artery disease (CAD) in which stress electrocardiogram (ECG), stress echocardiography, coronary computed tomography angiography (CCTA), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and cardiac magnetic resonance (CMR) can reclassify patients into a post-test probability that defines (>85%) or excludes (<15%) anatomically (defined by visual evaluation of invasive coronary angiography [ICA]) and functionally (defined by a fractional flow reserve [FFR] </=0.8) significant CAD. Methods and results: A broad search in electronic databases until August 2017 was performed. Studies on the aforementioned techniques in >100 patients with stable CAD that utilized either ICA or ICA with FFR measurement as reference, were included. Study-level data was pooled using a hierarchical bivariate random-effects model and likelihood ratios were obtained for each technique. The PTP ranges for each technique to rule-in or rule-out significant CAD were defined. A total of 28 664 patients from 132 studies that used ICA as reference and 4131 from 23 studies using FFR, were analysed. Stress ECG can rule-in and rule-out anatomically significant CAD only when PTP is >/=80% (76-83) and </=19% (15-25), respectively. Coronary computed tomography angiography is able to rule-in anatomic CAD at a PTP >/=58% (45-70) and rule-out at a PTP </=80% (65-94). The corresponding PTP values for functionally significant CAD were >/=75% (67-83) and </=57% (40-72) for CCTA, and >/=71% (59-81) and </=27 (24-31) for ICA, demonstrating poorer performance of anatomic imaging against FFR. In contrast, functional imaging techniques (PET, stress CMR, and SPECT) are able to rule-in functionally significant CAD when PTP is >/=46-59% and rule-out when PTP is </=34-57%. Conclusion: The various diagnostic modalities have different optimal performance ranges for the detection of anatomically and functionally significant CAD. Stress ECG appears to have very limited diagnostic power. The selection of a diagnostic technique for any given patient to rule-in or rule-out CAD should be based on the optimal PTP range for each test and on the assumed reference standard. [less ▲]

Detailed reference viewed: 17 (4 ULiège)
Full Text
Peer Reviewed
See detailMultimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging.
Fox, Kevin; Achenbach, Stephan; Bax, Jeroen et al

in European Heart Journal (2018)

Detailed reference viewed: 66 (3 ULiège)
Full Text
Peer Reviewed
See detailCardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council.
Lancellotti, Patrizio ULiege; Suter, Thomas M.; Lopez-Fernandez, Teresa et al

in European Heart Journal (2018)

Aims: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early ... [more ▼]

Aims: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termination. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European Society of Cardiology addressed the management of CV monitoring and management of patients treated for cancer. Methods and results: The current document is focused on the basis of the Cardio-Oncology (C-O) Services, presenting their rationale, organization, and implementation. C-O Services address the spectrum of prevention, detection, monitoring, and treatment of cancer patients at risk of cardiotoxicity and/or with concomitant CV diseases. These services require a multidisciplinary approach, with the aims of promoting CV health and facilitating the most effective cancer therapy. Conclusion: The expected growing volume of patients with cancer at risk of developing/worsening CV disease, the advent of new technological opportunities to refine diagnosis, and the necessity of early recognition of cancer therapy-related toxicity mandate an integrative multidisciplinary approach and care in a specialized environment. This document from the ESC Cardio-Oncology council proposes the grounds for creating C-O Services in Europe based on expert opinion. [less ▲]

Detailed reference viewed: 167 (1 ULiège)
Full Text
Peer Reviewed
See detailAddressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.
Cosentino, Francesco; Ceriello, Antonio; Baeres, Florian M. M. et al

in European Heart Journal (2018), 0

Detailed reference viewed: 33 (1 ULiège)
Full Text
Peer Reviewed
See detailPrediction of ischaemic stroke in non-valvular atrial fibrillation if advanced echocardiography plays the game.
Lancellotti, Patrizio ULiege; Galderisi, Maurizio

in European Heart Journal (2018), 39(16), 1426-1428

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailThe EACVI Echo Handbook.
Nchimi Longang, Alain ULiege

in European Heart Journal (2017)

Detailed reference viewed: 21 (1 ULiège)
Full Text
Peer Reviewed
See detailStandards defining a 'Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint.
Chambers, John B.; Prendergast, Bernard; Iung, Bernard et al

in European Heart Journal (2017), 38(28), 2177-2183

Detailed reference viewed: 49 (0 ULiège)
Full Text
Peer Reviewed
See detail2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H.; Falk, V.; Bax, J. J. et al

in European Heart Journal (2017), 38(36), 2739-2786

[No abstract available]

Detailed reference viewed: 910 (4 ULiège)